The Absorption Rate of Subcutaneous Infused Fluid
ABSU
1 other identifier
observational
6
1 country
1
Brief Summary
The purpose of the study is to examine the rate of absorption of subcutaneous infused fluid in older adults when acutely ill compared to when they are not acutely ill.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 28, 2020
CompletedStudy Start
First participant enrolled
September 1, 2020
CompletedFirst Posted
Study publicly available on registry
September 2, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 20, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 20, 2020
CompletedFebruary 4, 2021
February 1, 2021
3 months
August 28, 2020
February 2, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The difference in the absorption rate between acutely ill and not acutely ill.
We will compare the absorptions rate of subcutaneous infused fluid when the patients are acutely ill (during admission) and when they are not acutely ill (8 weeks after discharge).
8 weeks after discharge
Secondary Outcomes (3)
The absorption rate of subcutaneous infused fluid by count over the infusion site
We will count the activity from the start of infusions until 2 hours after all of the 250 ml have been infused.
The absorption rate of subcutaneous infused fluid by count in the thyroid or by count in blood samples.
We will count the activity from the start of infusions until 2 hours after all of the 250 ml have been infused.
The correlation between s-albumin and absorption time.
We will count the activity from the start of infusions until 2 hours after all of the 250 ml have been infused.
Interventions
Patients will twice receive a subcutaneous infusion of 250 ml isotonic sodium chloride (NaCl) with 30 MBq Tc-99m pertechnetate mixed in. The patients will receive the first infusion during admission to our geriatric ward (when they are acutely ill) and the second infusion approximately 8 weeks after discharge when they are no longer acutely ill. The subcutaneous access will be placed on the abdomen in the lower left or right quadrant.
Eligibility Criteria
Patients admitted to the local geriatric ward will be screened for eligibility.
You may qualify if:
- Ability to give informed consent
- Hospitalized for an acute illness
You may not qualify if:
- Severe limitation on fluids
- Risk of acute deterioration of illness
- Requiring constant care
- Short life expectancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Aalborg University Hospital
Aalborg, Denmark
Related Publications (1)
Danielsen MB, Jodal L, Riis J, Karmisholt JS, Valdorsson O, Jorgensen MG, Andersen S. Absorption rate of subcutaneously infused fluid in ill multimorbid older patients. PLoS One. 2022 Oct 10;17(10):e0275783. doi: 10.1371/journal.pone.0275783. eCollection 2022.
PMID: 36215232DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mathias B Danielsen, MD
Aalborg University Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD
Study Record Dates
First Submitted
August 28, 2020
First Posted
September 2, 2020
Study Start
September 1, 2020
Primary Completion
November 20, 2020
Study Completion
November 20, 2020
Last Updated
February 4, 2021
Record last verified: 2021-02
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, ANALYTIC CODE
- Time Frame
- Beginning 6 months and ending 5 years following article publication.
- Access Criteria
- The dataset will be shared upon reasonable request.
All of the individual participant data collected during the trial, after deidentification. Data sets will only be shared when the anonymity of included participants can be insured.